Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06), Zacks reports. Astellas Pharma had a return on equity of 25.79% and a net margin of 16.01%.
Astellas Pharma Stock Performance
Shares of ALPMY stock traded down $0.01 during midday trading on Wednesday, hitting $16.11. The company had a trading volume of 73,246 shares, compared to its average volume of 148,340. The company’s 50 day simple moving average is $15.03 and its 200 day simple moving average is $14.73. Astellas Pharma has a 52-week low of $10.64 and a 52-week high of $17.35. The stock has a market cap of $29.15 billion, a price-to-earnings ratio of 12.26 and a beta of 0.06. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93.
Analyst Upgrades and Downgrades
Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.
Read Our Latest Stock Analysis on Astellas Pharma
About Astellas Pharma
Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.
Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.
Further Reading
- Five stocks we like better than Astellas Pharma
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
- Bloom Energy: The Off-Grid Answer to AI’s Power Drain
- Space Race 2.0: Intuitive Machines Secures Another NASA Contract
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
